Rovalpituzumab tesirine

Extended indication	Small-cell lung cancer (SCLC), 3L.
Therapeutic value	No judgement
Registration phase	Withdrawn

Product

Active substance	Rovalpituzumab tesirine
Domain	Oncology and Hematology
Reason of inclusion	New medicine (specialité)
Main indication	Lung cancer
Extended indication	Small-cell lung cancer (SCLC), 3L.
Manufacturer	Abbvie
Route of administration	Intravenous
Therapeutical formulation	Intravenous drip
Budgetting framework	Intermural (MSZ)

Registration

Registration route	Centralised (EMA)
Type of trajectory	Normal trajectory
Orphan drug	Yes
Registration phase	Withdrawn
Additional remarks	Klinische studies zijn stopgezet.

Therapeutic value

Therapeutic value	No judgement

Expected patient volume per year

Patient volume	56 Market share is generally not included unless otherwise stated.
References	NKR; Expertopinie
Additional remarks	In 2016 werden er 1.118 diagnoses stadium 4 SCLC geregistreerd. Hiervan is de inschatting dat ongeveer 5% een behandeling in de derde lijn krijgt (56)

Patient volume

56

Market share is generally not included unless otherwise stated.

References

NKR; Expertopinie

Additional remarks

In 2016 werden er 1.118 diagnoses stadium 4 SCLC geregistreerd. Hiervan is de inschatting dat ongeveer 5% een behandeling in de derde lijn krijgt (56)

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension	No
References	SPS
Additional remarks	geen fase III studies voor andere indicaties dan in de horizonscan

Other information

There is currently no futher information available.